Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and paediatric recipients aged three months and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. Shares of Concord Biotech Ltd ended at ₹1,166.80, up by ₹106.20, or 10.01%, on the BSE today, June 2.
